Table 2.

Summary of main clinical trials evaluating oXiris-CRRT in COVID-19 patients.

Author	Publication Year	Country	Study Design	Sample Size	Main Findings
Padala [41]	2020	USA	case series	3	oXiris-CRRT decreased the levels of IL-6, the erythrocyte sedimentation rate, and CRP in critically ill patients with COVID-19.
Zhang [42]	2020	China	case series	5	Oxiris-CRRT might reduce the level of IL-6, IL-8, and CRP and improve the hemodynamic status as well as organ function.
Villa [46]	2020	Italy	prospective observational study	37	oXiris-CRRT was associated with a reduction in the serum IL-6 level, an attenuation in systemic inflammation, an improvement in multiorgan dysfunctions, and a decrease in the expected ICU mortality rate.
Rosalia [43]	2022	North Macedonia	prospective cohort study	44	oXiris-CRRT is associated with a reduction in ferritin, CRP, fibrinogen, and IL-6, and a resolution in numerous cytopenias.
Premužić [44]	2022	Zagreb Croatia	retrospective observational study	15	oXiris-CRRT provides a significant reduction in IL-6, an improvement in the respiratory status, and a reduction in SOFA score severity.
Ugurov [45]	2022	North Macedonia	case series	15	The combination of systemic heparin anticoagulation regimens and oXiris-CRRT might reduce hyperinflammation, prevent coagulopathy, and support clinical recovery.
Kang [47]	2022	China	prospective nonblind randomized controlled study	17	oXiris-CRRT showed no advantage in removing circulating cytokines and inflammatory chemokines in non-AKI patients with severe and critical COVID-19.

Abbreviations: CRRT represents continuous renal replacement therapy; CRP represents C-reactive protein; and IL represents interleukin.